Delving into the Latest Updates on Mizoribine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Mizoribine (JP17/INN), HE-69, NSC-289637

+ [3]

Target

IMPDH

Mechanism

IMPDH inhibitors(Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesUrogenital Diseases

Active Indication

Nephrotic SyndromeRheumatoid ArthritisLupus Nephritis+ [1]

Inactive Indication-

Originator Organization

Asahi Kasei Corp.

Active Organization

Asahi Kasei Corp.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (15 Feb 1984),

Renal transplant rejection

RegulationOrphan Drug (US)

Login to view First Approval Timeline

Structure

Molecular FormulaC9H13N3O6

InChIKeyHZQDCMWJEBCWBR-UUOKFMHZSA-N

CAS Registry50924-49-7

This prospective, randomized controlled study is intended to enroll 152 patients in the early stages of donor kidney transplantation at six clinical centers in China between January 2023 and January 2024. All patients meeting the inclusion criteria were randomly assigned 1:1 to either Mizoribine or Mycophenolate Mofetil for 12 months. At the baseline of follow-up (before enrollment) and each follow-up point, all clinical indicators of patients were recorded to measure the therapeutic effect.

Start Date01 Jan 2023

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

NCT05293704 / Unknown statusPhase 4

An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients

This study is divided into two parts: ① Part I was a retrospective observational study. Kidney transplant recipients infected with BK virus (BKV) in the First Affiliated Hospital of Sun Yat-sen University from 2015 to 2021 were retrospectively collected and divided into case group and control group whether to convert MPA drug to mizoribine. ② The second part was a prospective, open and interventional clinical trial. Thirty patients with positive urinary BK virus after kidney transplantation using Mycophenolic acid (MPA) were enrolled in the First Affiliated Hospital of Sun Yat-sen University. All patients who met the inclusion criteria were treated with mizoribine to place MPA (Mycophenolate or mycophenolate sodium enteric coated tablets) for 12 months as directed. At the baseline of follow-up (before enrollment) and at each follow-up point, clinical indicators of patients were recorded, and renal biopsy was performed to evaluate the occurrence of BKV nephropathy in patients with persistent elevated BK viruria or persistent BK viremia after conversion and patients with BK viruria after 12 months, and to judge the progress after early activation of BKV and the safety of mizoribine.

Start Date01 May 2022

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

JPRN-jRCTs051200070 / CompletedPhase 2IIT

Efficacy of mizoribine after two years of cyclosporine treatment for children with frequently relapsing nephrotic syndrome

Start Date23 Dec 2020

Sponsor / Collaborator-

100 Clinical Results associated with Mizoribine

Login to view more data

100 Translational Medicine associated with Mizoribine

Login to view more data

100 Patents (Medical) associated with Mizoribine

Login to view more data

700

Literatures (Medical) associated with Mizoribine

01 Dec 2023·Gan to kagaku ryoho. Cancer & chemotherapy

[A Case Report of the Ascending Colon Cancer with Bullous Pemphigoid].

Review

Author: Dono, Keizo ; Odagiri, Kazuki ; Takeyama, Hiroshi ; Yanagimoto, Yoshitomo ; Shimizu, Junzo ; Yamashita, Masafumi ; Kawase, Tomono ; Iijima, Ken ; Suzuki, Yozo ; Ikenaga, Masakazu ; Tomita, Naohiro ; Imamura, Hiroshi

The patient was a 70-year-old man. The patient had progressive anemia while taking 10 mg/day of prednisolone and 100 mg/day of mizoribine orally for bullous pemphigoid, a colonoscopy diagnosed ascending colon cancer. Adenocarcinoma, Group 5 was detected on biopsy. Abdominal computed tomography showed no metastases. The tumor was diagnosed as ascending colon cancer, cT4aN0M0, cStage Ⅱb. We performed laparoscopic right hemicolectomy and D3 dissection. Histopathological examination revealed pT3N0M0, pStage Ⅱa. In the present report, we describe a case of the ascending colon cancer with bullous pemphigoid, and discuss the case with a review of the literature.

01 Dec 2023·Pediatric nephrology (Berlin, Germany)

Long-term outcome of combination therapy with corticosteroids, mizoribine and RAS inhibitors as initial therapy for severe childhood IgA vasculitis with nephritis

Article

Author: Aoto, Yuya ; Yoshikawa, Norishige ; Fujimura, Junya ; Ninchoji, Takeshi ; Kitakado, Hideaki ; Horinouchi, Tomoko ; Sakakibara, Nana ; Ishimori, Shingo ; Ueda, Chika ; Tanaka, Ryojiro ; Nozu, Kandai ; Iijima, Kazumoto ; Ichikawa, Yuta ; Tanaka, Yu ; Shima, Yuko ; Nakanishi, Koichi ; Nagai, Sadayuki ; Kaito, Hiroshi ; Kondo, Atsushi ; Kamiyoshi, Naohiro

BACKGROUND:

Patients with severe IgA vasculitis with nephritis (IgAVN) typically receive aggressive therapy as an initial approach. We have consistently performed combination therapy including corticosteroids and immunosuppressants as initial therapy for severe IgAVN over a 20-year-plus period, with only minor changes to the treatment protocol. This study seeks to reveal the efficacy of combination therapy for severe IgAVN.

METHODS:

We retrospectively studied 50 Japanese children diagnosed between 1996 and 2019 with clinicopathologically severe IgAVN who were defined as ISKDC classification grade IIIb-V and/or serum albumin < 2.5 g/dL.

RESULTS:

The median age at the onset of IgAVN was 8.0 years (IQR: 6.0-10.0). At biopsy, 44% of patients had nephrotic syndrome and 14% had kidney dysfunction. All patients were treated with combination therapy after biopsy. Abnormal proteinuria resolved after initial therapy in all 50 patients. However, eight patients (16%) had recurrence of proteinuria. Abnormal proteinuria was again resolved in three of these patients with additional treatment. At the last follow-up (median 59.5 months; IQR, 26.2-84.2), the median urine protein-to-creatine ratio was 0.08 g/gCr (IQR, 0.05-0.15), and only one patient had kidney dysfunction.

CONCLUSIONS:

Combination therapy provided good kidney outcomes for Japanese children with severe IgAVN. Even including recurrent cases, the degree of proteinuria was slight, and kidney function was good at the last follow-up. A higher resolution version of the Graphical abstract is available as Supplementary information.

01 Nov 2023·Clinical and experimental nephrology

Demographics and treatment of patients with primary membranoproliferative glomerulonephritis in Japan using a national registry of clinical personal records.

Article

Author: Narita, Ichiei ; Kimura, Tomonori ; Isaka, Yoshitaka ; Nakagawa, Naoki ; Sakate, Ryuichi

BACKGROUND:

Membranoproliferative glomerulonephritis (MPGN) is a rare glomerular injury that causes nephrotic syndrome and end-stage kidney disease. The nationwide demographics and treatment of Japanese patients with primary MPGN have not yet been reported.

METHODS:

We collected clinical personal records of patients with primary MPGN between 2015 and 2018 from the national registry organized by the Japanese Ministry of Health, Labour, and Welfare and investigated the characteristics of primary MPGN throughout Japan.

RESULTS:

Of 258 patients with primary MPGN, 199 and 59 showed nephrotic and non-nephrotic syndrome, respectively. The median age at onset was higher in patients with nephrotic syndrome than in those with non-nephrotic syndrome (45 [24-63] vs. 35 [14-53] years, respectively; P = 0.010). The use of oral prednisolone was significantly higher in patients with nephrotic syndrome than in those with non-nephrotic syndrome (73.9% vs. 59.3%, respectively; P = 0.032). When patients were divided into three age groups: adolescent and young adult group (≤ 39 years; n = 80), middle adult group (40-64 years; n = 111), and older adult group (≥ 65 years; n = 67), the use of oral prednisolone, cyclosporine, and mizoribine was significantly higher in the adolescent and young adult group than in the middle adult group. The mean dosage of oral prednisolone and mizoribine showed no differences among the three age groups.

CONCLUSION:

The national registry of clinical personal records of primary MPGN could provide an informative insight into the characteristics, clinical features, and treatment approaches for patients with primary MPGN in Japan.

100 Deals associated with Mizoribine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01392	Mizoribine	L04AX	DB12617

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Nephrotic Syndrome	JP	Asahi Kasei Corp.	29 Sep 1995
Rheumatoid Arthritis	JP	Asahi Kasei Corp.	02 Oct 1992
Lupus Nephritis	JP	Asahi Kasei Corp.	28 Sep 1990
Renal transplant rejection	JP	Asahi Kasei Corp.	15 Feb 1984

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2021	Not Applicable	Glomerulonephritis, IGA	84	Previous combination therapy (PSL and MZB)	mejjewqpmc(qzsdkyaiwn) = obwusdnnjf yrbsgswkip (lmkhkbeayj ) View more	Positive	27 Oct 2021
				New combination therapy (PSL, MZB, and lisinopril)	mejjewqpmc(qzsdkyaiwn) = ymogpsduki yrbsgswkip (lmkhkbeayj ) View more
ASN2019	Not Applicable	Glomerulonephritis, IGA CD163 + \| CD300e	73	Prednisolone (PSL) plus Mizoribine (Miz)	nhjvemfpty(vofvccsbuy) = the number of interstitial CD163 + MQ were significantly reduced in the PM group, but not in the P group rnlsdovfvx (gjaipvhwfg ) View more	Positive	05 Nov 2019
FP227 (ERA2019)	Not Applicable	Idiopathic Membranous Glomerulonephritis anti-phospholipase A2 receptor antibody (PLA2R-Ab)	-	Mizoribine 150 mg + Prednisolone 30 mg	nagykzcuwb(kvbhykqmgl) = zcvpqtzdbd ynnlazytlp (nnsqgqvcmi )	Positive	13 Jun 2019
				Prednisolone 30 mg	nagykzcuwb(kvbhykqmgl) = ngsejvdfcy ynnlazytlp (nnsqgqvcmi )
Pubmed \| Transplant Proc	Not Applicable	-	-	Mizoribine, Tacrolimus, Corticosteroids	srpyqdswux(vaqnwlblrn) = bvkjdsnage ckjujrxjwd (eevkimuodi ) View more	-	01 Jun 2019
				Mycophenolate mofetil, Tacrolimus, Corticosteroids	srpyqdswux(vaqnwlblrn) = dadmenmvlj ckjujrxjwd (eevkimuodi ) View more
ASN2017	Not Applicable	Idiopathic Membranous Glomerulonephritis anti-phospholipase A2 receptor antibody (PLA2R-Ab)	-	Mizoribine 150 mg + Prednisolone 30 mg	aeysnwcjrt(sjrlcptaqb) = fihzmlbngx czvnpjszre (xpykkkuunf )	Positive	31 Oct 2017
EULAR2017	Not Applicable	Lupus Nephritis	47	Mizoribine, Tacrolimus, and Prednisolone	aefbyxmrcd(ghmijpdfju) = 14 cases had some Infection, 3 out of 14 needed antibiotics treatment xqhtcuqyiy (cfqbnqynfr ) View more	Positive	14 Jun 2017
MP226 (ERA2017)	Not Applicable	Idiopathic Membranous Glomerulonephritis anti-phospholipase A2 receptor (PLA2R)	-	Mizoribine 150 mg + Prednisolone 30 mg	pudbmajqqp(yrtjtitvtn) = vbuyzvplwx uedlpzpkhv (wkzkbnqovz ) View more	Positive	26 May 2017
				Prednisolone 30 mg	pudbmajqqp(yrtjtitvtn) = gpffwqiwgv uedlpzpkhv (wkzkbnqovz ) View more
EULAR2016	Not Applicable	Polymyalgia Rheumatica	24	Mizoribine	jpmwgfyxtx(nkznfacgii) = 1 patient developed gastrointestinal symptom in MTX group, and 1 patient developed gastrointestinal symptom in MZR group emweiyryhd (sihwfrwmfh ) View more	Positive	08 Jun 2016
				Methotrexate
EULAR2015	Not Applicable	Lupus Nephritis	576	Mizoribine	mtmqblixek(vkfpaiuycv) = Adverse reactions occurred in 60 of the 443 subjects (13.5%). The main adverse reactions were 12 events (2.7%) of herpes zoster, 5 events (1.1%) of hyperuricemia, and 4 events (0.9%) of anemia. Serious adverse drug reactions were observed in 12 patients (2.7%) ghlmqknciz (nhalcyvysm )	Positive	10 Jun 2015
ASN2014	Not Applicable	Glomerulonephritis, IGA	-	Pulse methylprednisolone followed by 2-year course of oral prednisolone	hbyeqjnqed(xrfjclfcdc) = bbqmdwuzav fgmqalisqj (ghxhmgnnme ) View more	Negative	11 Nov 2014
				Mizoribine (150 mg/day for 2 years) in combination with pulse methylprednisolone followed by 2-year course of oral prednisolone	hbyeqjnqed(xrfjclfcdc) = wcohmdrsey fgmqalisqj (ghxhmgnnme ) View more